AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

AstraZeneca said it has created more than 1,200 jobs and invested more than $1.3-billion CAD in Canada since 2023. The ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

Shares of AstraZeneca PLC AZN inched up 0.04% to £110.50 Friday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.73% to 8,502.35.